Author Page for Matthew Jordan

Response to USPTO’s Patent Eligibility Jurisprudence Study (Docket No.: PTO–P–2021–0032)

University of Cambridge Faculty of Law Research Paper No. 9/2023

Number of pages: 156 Posted: 11 Oct 2021 Last Revised: 05 Apr 2023

Mateo Aboy, Kathleen Liddell, Cristina Crespo, John Liddicoat and Matthew Jordan

LML, University of Cambridge, University of Cambridge - Faculty of Law, University of Cambridge, King’s College London and University of Cambridge - Faculty of Law

Downloads 130 (475,671)

Abstract:

2.

Repositioning Generic Drugs: Empirical Findings and Policy Implications

International Review of Intellectual Property & Competition Law | 53, pages 1287–1322 (2022)

Number of pages: 36 Posted: 21 Sep 2023

John Liddicoat, Kathleen Liddell, Jonathan J. Darrow, Mateo Aboy, Matthew Jordan, Cristina Crespo and Timo Minssen

King’s College London, University of Cambridge - Faculty of Law, Harvard Medical School, LML, University of Cambridge, University of Cambridge - Faculty of Law, University of Cambridge and University of Copenhagen - Centre for Advanced Studies in Biomedical Innovation Law (CeBIL) - Faculty of Law

Downloads 121 (503,060)

Abstract:

3.

After Myriad, What Types of Claim Amendments Change a Patent Ineligible Isolated Gene Claim Into an Eligible Patent Claim That Is ‘Markedly Different’ From Nature?

35 Nature Biotechnology 820-825

Number of pages: 31 Posted: 22 May 2018

Mateo Aboy, John Liddicoat, Kathleen Liddell, Matthew Jordan and Cristina Crespo

LML, University of Cambridge, King’s College London, University of Cambridge - Faculty of Law, University of Cambridge - Faculty of Law and University of Cambridge

Downloads 111 (537,039)

Citation 2

Abstract:

4.

Was the Myriad Decision a ‘Surgical Strike’ on Isolated DNA Patents, or Does it Have Wider Impacts?

36(12) Nature Biotechnology 1146

Number of pages: 6 Posted: 27 Jun 2019 Last Revised: 18 Sep 2019

Mateo Aboy, Cristina Crespo, Kathleen Liddell, John Liddicoat and Matthew Jordan

LML, University of Cambridge, University of Cambridge, University of Cambridge - Faculty of Law, King’s College London and University of Cambridge - Faculty of Law

Downloads 76 (685,583)

Citation 1

Abstract:

5.

IP Policies for Large Bioresources: The Fiction, Fantasy and Future of Openness

Global Genes, Local Concerns (2019), University of Cambridge Faculty of Law Research Paper No. 2/2020

Number of pages: 20 Posted: 10 Jun 2019 Last Revised: 21 May 2020

Kathleen Liddell, John Liddicoat and Matthew Jordan

University of Cambridge - Faculty of Law, King’s College London and University of Cambridge - Faculty of Law

Downloads 67 (734,987)

Matthew Jordan

University of Cambridge - Faculty of Law

5

505

3

Scholarly Papers (5)

Response to USPTO’s Patent Eligibility Jurisprudence Study (Docket No.: PTO–P–2021–0032)

Abstract:

Repositioning Generic Drugs: Empirical Findings and Policy Implications

Abstract:

After Myriad, What Types of Claim Amendments Change a Patent Ineligible Isolated Gene Claim Into an Eligible Patent Claim That Is ‘Markedly Different’ From Nature?

Abstract:

Was the Myriad Decision a ‘Surgical Strike’ on Isolated DNA Patents, or Does it Have Wider Impacts?

Abstract:

IP Policies for Large Bioresources: The Fiction, Fantasy and Future of Openness

Abstract: